Premium
Jaundice and intrahepatic cholestasis following high‐dose megestrol acetate for breast cancer
Author(s) -
Foitl Daniel R.,
Hyman George,
Lefkowitch Jay H.
Publication year - 1989
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19890201)63:3<438::aid-cncr2820630307>3.0.co;2-o
Subject(s) - megestrol acetate , medicine , jaundice , megestrol , progestin , cholestasis , adverse effect , cancer , gastroenterology , estrogen
High‐dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high‐dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.